ABL1 and chronic myelogenous leukemia, BCR-ABL1 positive: Pharmacological agents that target BCR-ABL-independent molecular targets in CML by initiating non-apoptotic cell death may overcome both BCR-ABL- and apoptosis-related resistance mechanisms by targeting unrelated vulnerabilities of CML cells specifically related to oxidative and metabolic stress metabolism.